That is precisely why I said the company has rights to the N-Assay patent. A highly positioned company executive who is in charge of the company's research agenda and strategy has a fiduciary duty to the company to take actions that benefit the company. When that fiduciary duty, company funds, product focus, public pronouncements by researchers who indicate they are doing this with NanoLogix, and clear statements that the company is developing the technology and that it is its tech future then regardless of the specific names on the patent the company controls. That does not mean absolutely that there can't be royalty arrangements but does mean that NanoLogix is in control. Now could people just focus on the positive future of the company and stop obsessing about the N-Assay patent?